(Update: On November 4, 2021, the NIH provided a response to our comments on the license.) On October 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the ““Prospective Grant of an Exclusive… Continue Reading
On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).
We have received a copy of an amendment to the September 2006 voluntary License Agreement between Gilead Sciences, Inc and Ranbaxy Laboratories, Ltd concerning the manufacture and sale of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine for the treatment of HIV-AIDS.
The following are selected cables from the US Department of State, obtained under the U.S. FOIA statutes, concerning patents and price negotiations on AIDS drugs. 2004 U.S. DoS Cable: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS – January… Continue Reading
R 131556Z – October 13, 2005FM AMEMBASSY BRAZILIATO SECSTATE WASHDC 3176SUBJECT: ABBOTT AND GOB REACH DEAL TO AVOID COMPULSORY LICENSE 1. SENSITIVE BUT UNCLASSIFIED – PLEASE TREAT ACCORDINGLY 2. (U) Summary. On October 10, Abbott Laboratories and Brazil’s Ministry of… Continue Reading
R 122031Z AUG 05 – August 12, 2005FM AMEMBASSY BRASILIATO SECSTATE WASHDC 2501SUBJECT: Brazil’s National Health Council Recommends Compulsory Licensing of Antiretrovirals 1. SENSITIVE BUT UNCLASSIFIED 2. (SBU) Summary. Adding to the tension surrounding negotiations between the ministry of… Continue Reading